Every round on record, with the sources behind each and the investors on them.
Desentum develops novel allergen immunotherapy products aimed at treating allergies, primarily targeting birch pollen, peanuts, and cat allergies, which is purchased by patients seeking allergy relief.
desentum.fiLinkedInFinlandBiotechFounded 2011
2 sources
Developing: it holds up against its sources so far, and firms up as more reporting lands.
Springvest is described as arranging the round and as an existing major shareholder, but no source calls it a round investor or lead. The reported EUR 54 million is the total Springvest has arranged for Desentum to date, not this round's financing total.
2 sources
Developing: it holds up against its sources so far, and firms up as more reporting lands.
Springvest Oyj is described as arranging and carrying out the round, not as an investor; no lead or participating investors are stated.
2 sources
Developing: it holds up against its sources so far, and firms up as more reporting lands.
Springvest Oyj is described as arranging and carrying out the funding round, not as an investor. No round stage, valuation, or financing total is stated.
1 source
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The company announces a crowdfunding campaign, but no formal stage or named investors are stated.
1 source
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The company release identifies the financing as a Series A and states the round amount as EUR 1.85 million.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Funding round | $31.4M €28 million | 2026-10-12 | not stated | 2 outlets. #12 in Trending |
2 sources [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 2 sources Springvest is described as arranging the round and as an existing major shareholder, but no source calls it a round investor or lead. The reported EUR 54 million is the total Springvest has arranged for Desentum to date, not this round's financing total. | ||||
Desentum develops allergy immunotherapy products that retrain the immune system to tolerate allergens, for people with respiratory and food allergies.
Checked against 10 sources today
| Funding round [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $12.9M 12 M€ | ~ 2024-01 | not stated | No recent discussion |
2 sources [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 of 2 sources Springvest Oyj is described as arranging and carrying out the round, not as an investor; no lead or participating investors are stated. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]2 pages read: desentum.fi, en.ain.ua·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]confirmedchecked against 1 of 2 sources·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent | ||||
| Funding round [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $9.1M 8 M€ | 2022-01-21 | not stated | No recent discussion |
2 sources [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 2 sources
Springvest Oyj is described as arranging and carrying out the funding round, not as an investor. No round stage, valuation, or financing total is stated. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]2 pages read: desentum.fi, news.cision.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 2 sources·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent | ||||
| Crowd funding campaign [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $2.7M EUR 2.3 million | 2017-11-29 | not stated | No recent discussion |
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source The company announces a crowdfunding campaign, but no formal stage or named investors are stated. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: desentum.fi·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]confirmedchecked against 1 source·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent | ||||
| Series A [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $2.0M EUR 1.85 million | 2017-01-23 | not stated | No recent discussion |
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source The company release identifies the financing as a Series A and states the round amount as EUR 1.85 million. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: desentum.fi·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 source·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent | ||||
| EARLIER ROUNDS FROM COMPANY RESEARCH · DEVELOPING | ||||
| Share issue | 18 M€ | 2026-04-27 | not stated | |
| Funding round | 4 million euros | 2019-11-01 | not stated | |
Also named as backers in company research: Business Finland, European Innovation Council, Springvest